^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    MK-4166

    i
    Other names: MK-4166, MK 4166
    Associations

    News

    Trials
    Company:
    Merck (MSD)
    Drug class:
    GITR agonist
    Related drugs:
    Associations

    News

    Trials
    almost5years
    Phase I Study of MK-4166, an Anti-Human Glucocorticoid-Induced Tumor Necrosis Factor Receptor Antibody, Alone or With Pembrolizumab in Advanced Solid Tumors. (PubMed, Clin Cancer Res)
    MK-4166 900 mg IV Q3W as monotherapy and with pembrolizumab was tolerable. Responses were observed with combination therapy, mostly in patients with ICI-naive melanoma.
    P1 data • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    TNFA (Tumor Necrosis Factor-Alpha)
    |
    Keytruda (pembrolizumab) • MK-4166